BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018.

Sanofi has inaugurated a new assembling and packaging line to produce its flagship pre-filled insulin injection pen Lantus SoloSTAR at its Beijing plant located at the Beijing Economic-Technological ...

Switzerland-based Sandoz, a global leader in affordable medicines, today confirmed that the European Commission has granted ...

NEW YORK Sanofi-aventis’ SoloSTAR insulin pen has some serious competition. Two independent studies in Germany and Japan have found that Novo Nordisk’s FlexPen was more accurate in delivering insulin ...

The US Court of Appeals for the First Circuit held that pharmaceutical companies that wrongly list patents in FDA’s Orange Book must prove they acted in good faith to avoid antitrust liability. In re ...

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL +0.00%) and Biocon's Semglee, which is essentially identical to ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...